Stock 4588 ONCOLYS BIOPHARMA INC.
Add to a list
To use this feature you must be a member
Log inSign up

Oncolys BioPharma Inc. Stock

Equities

4588

JP3202170001

Pharmaceuticals

Market Closed - Japan Exchange
Other stock markets
 02:00:00 2024-07-05 am EDT 		5-day change 1st Jan Change
548 JPY +0.18% Intraday chart for Oncolys BioPharma Inc. 0.00% -3.35%
Jun. 14 Oncolys BioPharma Inc. announced that it expects to receive ¥2.2 million in funding CI
Jun. 03 Medigen Biotechnology Corp. and Oncolys BioPharma Enroll First Participant in Investigator-Initiated Phase II Clinical Trial CI

Chart Oncolys BioPharma Inc.

Dynamic Chart

Latest news about Oncolys BioPharma Inc.

Oncolys BioPharma Inc. announced that it expects to receive ¥2.2 million in funding CI
Medigen Biotechnology Corp. and Oncolys BioPharma Enroll First Participant in Investigator-Initiated Phase II Clinical Trial CI
Oncolys BioPharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Medigen Biotechnology Corp. Announces Signing of the Sales Cooperation Agreement for the New Drug OBP-301 in Japan CI
Oncolys Biopharma Inc. Announces the Investigator-Initiated Phase 2 Clinical Trial Agreement with Weill Cornell Medicine CI
Oncolys Biopharma Inc. Provides Update on Phase II Study of Telomelysin (OBP-301) in Combination with Pembrolizumab in Gastroesophageal Adenocarcinoma CI
Oncolys Biopharma Announces Enrollment of First Expansion Cohort Patient in Phase I Clinical Trial for Telomelysin (OBP-301)-Chemoradiation Combination Therapy CI
Oncolys BioPharma Inc. Announces Achievement of Primary Endpoint for Efficacy in the Phase2 Clinical Trial for Telomelysin-Radiation Combination Therapy CI
Oncolys Biopharma Announces Meeting of Safety Endpoint in the Initial Safety Cohort of the Phase I Clinical Trial for Telomelysin?? in Combination Therapy CI
Oncolys BioPharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Oncolys Biopharma Partner Enrolls First Patient in Phase IIa Study of Aicardi-Goutières Syndrome Drug MT
Oncolys Biopharma Inc. Announces Enrollment of First Patient in Phase Iia Study for Obp-601 in Patients with Aicardi-Goutieres Syndrome CI
Oncolys BioPharma Inc. announced that it has received ¥21.106 million in funding from SMBC Nikko Securities Inc., Investment Arm CI
Oncolys BioPharma Inc. announced that it expects to receive ¥21.106 million in funding from SMBC Nikko Securities Inc., Investment Arm CI
Oncolys BioPharma Announces Results from an Investigator-Initiated Phase II Clinical Trial for Telomelysin™? (OBP-301) in Combination with Pembrolizumab in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma CI
More news

Press releases Oncolys BioPharma Inc.

Oncolys BioPharma : Announcement of Investigator-Initiated Phase 2 Clinical Trial Agreement For Immunotherapy refractory Esophagogastric adenocarcinoma PU
Oncolys BioPharma : Achievement of Primary Endpoint for Efficacy in the Phase2 Clinical Trial for Telomelysin-Radiation Combination Therapy PU
ASCO 2023 ANNOUNCEMENT: Encouraging Preliminary Data of OBP-301 with Pembrolizumab in refractory gastroesophageal adenocarcinoma PU
Oncolys BioPharma : Non-consolidated Financial Results for the Three Months Ended March 31, 2023 PU
Oncolys BioPharma : Non-consolidated Financial Results for the Nine Months Ended September 30, 2022 PU
More press releases

Quotes and Performance

1 day+0.18%
1 month-17.10%
3 months-21.94%
6 months-5.52%
Current year-3.35%
More quotes

Highs and lows

1 week
528.00
Extreme 528
560.00
1 month
483.00
Extreme 483
720.00
Current year
483.00
Extreme 483
798.00
1 year
483.00
Extreme 483
798.00
3 years
466.00
Extreme 466
1 460.00
5 years
466.00
Extreme 466
3 820.00
10 years
401.00
Extreme 401
4 410.00
More quotes

Managers and Directors - Oncolys BioPharma Inc.

Managers TitleAgeSince
Yasuo Urata FOU
 Founder 68 04-03-17
Kohei Hata DFI
 Director of Finance/CFO - 18-12-31
Yasunari Kashihara BRD
 Director/Board Member 58 07-11-30
Members of the board TitleAgeSince
Yasuo Urata FOU
 Founder 68 04-03-17
Naoko Iino BRD
 Director/Board Member 64 23-02-28
Yasunari Kashihara BRD
 Director/Board Member 58 07-11-30
More insiders

Quotes

Date Price Change Volume
24-07-05 548 +0.18% 153,600
24-07-04 547 +0.74% 294,600
24-07-03 543 +1.12% 181,300
24-07-02 537 +1.51% 445,000
24-07-01 529 -3.47% 336,100

Delayed Quote Japan Exchange, July 05, 2024 at 02:00 am EDT

More quotes

Company Profile

Oncolys BioPharma Inc. is a biopharmaceutical company. The Company operates in two business segments. Pharmaceutical business segment is engaged in the research, development, manufacture and marketing of pharmaceuticals. Diagnostic reagents business segment is engaged in the research, development, manufacture and marketing of diagnostic reagents and equipment, as well as the provision of inspection service. The Company's main pipeline includes OBP-301 (Telomelysin), an oncolytic virus; OBP-801, an epigenetic anticancer drug and OBP-601 for the treatment of human immunodeficiency virus (HIV) infection, among others.
Sector
Pharmaceuticals
Calendar
2024-08-08 - Q2 2024 Earnings Release
More about the company

Income Statement Evolution

More financial data

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
ONCOLYS BIOPHARMA INC. Stock Oncolys BioPharma Inc.
-3.35% 71.18M
CSL LIMITED Stock CSL Limited
+4.57% 97.7B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+5.66% 41.43B
BIOGEN INC. Stock Biogen Inc.
-12.80% 32.85B
UCB Stock UCB
+80.99% 29.33B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-15.53% 15.47B
INCYTE CORPORATION Stock Incyte Corporation
-8.70% 12.89B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-12.22% 11.51B
ALTEOGEN INC. Stock ALTEOGEN Inc.
+183.25% 10.74B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+3.60% 8.97B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. 4588 Stock